River Wealth Advisors’s CASI Pharmaceuticals CASI Stock Holding History

River Wealth Advisors’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5	Closed	–	–	196
2018 Q4	$0	Hold	5	–	–	﹤0.01%	544
2018 Q3	$0	Buy	+5	New	+$349	﹤0.01%	575

Other funds holding CASI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

River Wealth Advisors's CASI Position: Q1 2019 in Review

River Wealth Advisors sold out of CASI Pharmaceuticals (CASI) in Q1 2019, closing a stake of 5 shares.

River Wealth Advisors first reported a position in CASI in Q3 2018 and held it in 2 quarters. The position peaked at $0 in Q4 2018. 52 funds tracked by Wall St. Rank hold CASI as of Q1 2019.

River Wealth Advisors reported no remaining CASI Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
River Wealth Advisors sold 5 CASI Pharmaceuticals shares in Q1 2019.
River Wealth Advisors first reported a position in CASI Pharmaceuticals in Q3 2018 and held it in 2 quarters.
River Wealth Advisors's CASI Pharmaceuticals position peaked at $0 in Q4 2018.
52 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2019.

Based on River Wealth Advisors's 13F filing for Q1 2019, filed 7 May 2019.